期刊文献+

西格列汀联合格列美脲治疗2型糖尿病的临床观察 被引量:14

THERAPEUTIC EFFECT OF SITAGLIPTIN COMBINED WITH GLIMEPIRIDE IN TREATMENT OF TYPE 2 DIABETES
原文传递
导出
摘要 目的探讨西格列汀联合格列美脲治疗2型糖尿病的疗效。方法将38例2型糖尿病患者随机分为二组,治疗组18例,用西格列汀联合格列美脲进行治疗,对照组20例应用格列美脲单药治疗,观察12周。比较二组患者治疗前后空腹血糖(FBG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)、低血糖发生率、体重指数(BMI)变化情况。结果治疗12周后,治疗组与对照组的FBG、2hPG、HbA1c、BMI均明显下降,但联合治疗组的各项指标更接近理想目标。结论西格列汀联合格列美脲治疗2型糖尿病疗效确切,且有效控制患者体重,但增加了低血糖事件发生率。 Objective To explore the clinical effect of Sitagliptin combined with Glimepiride in treatment of type 2 diabetes. Methods The thirtyeight diabetie patients were randomly devided into two groups, control group(20 cases) were given Glimepiride tablets, treatment group (18 cases)received Sitagliptin phosphate tablets for 12 weeks. The change of FPG, PPG, H bA1 c, hypoglycemia happen rate, weight were observed in two groups. Results Compared with pretherapy;the levels of FBG,2hPG, HbAlc,BMI were obviously descendent (P〈0.05), but the elevels of markers were more approach their ideal goal in treatment group. Conclusion Sitagliptin conbined with Glimepiride can effectively control type 2 Diabetie patient's glucose and decrease weight gain, but increase the risk of hypoglycemia.
出处 《中国煤炭工业医学杂志》 2011年第12期1741-1742,共2页 Chinese Journal of Coal Industry Medicine
关键词 西格列汀 格列美脲 2型糖尿病 Sitagliptin Glimepiride type 2 Diabetie
  • 相关文献

参考文献8

二级参考文献52

  • 1李永强,冯志强,宋宏锐,郭彦伸,郭宗儒.葡萄糖激酶及其小分子活化剂研究进展[J].药学学报,2006,41(5):390-394. 被引量:9
  • 2沙向阳,张惠斌,周金培.以二肽基肽酶Ⅳ为靶点的抗糖尿病药物[J].药学进展,2006,30(6):241-246. 被引量:3
  • 3TAKASHI K, TAKAHIRO N, ISAMU S, et al. Design and synthesis of new potent dipeptidyl peptidase 1V inhibitors with enhanced ex vivo duration [ J ]. Bioorg Med Chem, 2007,15 ( 7 ) : 2631 - 2650. 被引量:1
  • 4XU J Y,WEI L,MATHVINK R,et al. Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors[ J]. Bioorg Med Chem Lett, 2005,15 (10) :2533 - 2536. 被引量:1
  • 5TOMOHIRO Y, HIROSHI S, FUMIHIKO A, et al. [ ( S ) -γ-( 4-Aryl-1-piperazinyl ) -L-prolyl ] thiazolidines as a novel series of highly potent and long-lasting DPP-Ⅳ inhibitors [ J]. Bioorg Med Chem Lett,2007,17(9) :2618 -2621. 被引量:1
  • 6THORNBERRY N A, WEBER A E. Discovery of januvia( sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[ J]. Curr Top Med Chem,2007,7(6) :557 -568. 被引量:1
  • 7SCHON E,BORN I. Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes [ J ]. Biol Chem Hoppe-Seyler, 1991,372(5) :305 - 311. 被引量:1
  • 8PEDERSON R A, WHITE H A. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide [J]. Diabetes, 1998,47 ( 8 ) :1253 - 1258. 被引量:1
  • 9XU J Y, HYUN O O EDWARD J G, et al. Discovery of potent and selective β-homophenylalanine based dipeptidyl peptidase IV intfibitors [ J ]. Bioorg Med Chem Lett,2004,14(18) :4759 - 4762. 被引量:1
  • 10BROCKUNIER L,HE J,COLWELL L F,et al. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors [ J ]. Bioorg Med Chem Lett, 2004, 14 (18) :4763 -4766. 被引量:1

共引文献503

同被引文献112

引证文献14

二级引证文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部